This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The company has partnerships with organizations such as the Mayo Clinic, the University of California, San Francisco, and the Veterans Health Administration. Palantir's products are also being used by pharmaceutical companies, medical device manufacturers, and healthcare payers. Palantir's plans for healthcare are ambitious.
Wearable monitoring devices, genomics, and AI play vital roles in this transformation, enabling personalized interventions and collective health data sharing for research. Drugdevelopment The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. She was the patient keynote speaker at DPHARM 2021 and is a HIMSS Digital Health Influencer.
Even though health officials readily admit that diabetes is an urgent publichealth problem, a new diabetes medicine or device usually finds itself in ninth position on the FDA docket for a pre-market clearance. To understand why requires an understanding of the history of the FDA, and its limitations.
The quickly evolving COVID-19 publichealth emergency has warranted the growing use of telehealth and non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact and possible exposure to the virus.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content